Pfizer opens R&D hub in US Cambridge
pharmafile | June 17, 2014 | News story | Manufacturing and Production, Research and Development, Sales and Marketing | Cambridge, Massachusetts, Pfizer, kit, manufacturing, research
Pfizer has open a new 280,000 sq.ft. R&D hub in Cambridge, Massachusetts which also serves to bring together 1,000 of its colleagues from three area locations.
According to the pharma giant the move was made in order to position itself in closer proximity to leading academic institutions, hospitals and patient organisations.
“We are thrilled to welcome Pfizer’s new R&D hub to the Kendall Square innovation district,” says Massachusetts Institute of Technology (MIT) president L. Rafael Reif.
“We could not ask for a more exciting tenant for these spaces. With this extraordinary core of Pfizer research teams now right next door to our labs at MIT, we can capitalise on the power of proximity to speed progress towards solutions to urgent challenges in human health.”
In addition to the new hub, Massachusetts is home to Pfizer’s research and manufacturing site in Andover and is the global headquarters for Pfizer’s Centers for Therapeutic Innovation (CTI) in Boston.
Led by Pfizer group VP of BioTherapeutics R&D, José-Carlos Gutiérrez-Ramos, the new laboratory facilities are leased from the MIT and Pfizer’s scientists will work there on a range of clinical programmes including inflammation, immunology, rare disease, cardiovascular and metabolic diseases, and neuroscience.
Pfizer’s president of R&D Mikael Dolsten says: “Having all of our Cambridge-area researchers working closely together in one of the world’s most exciting biomedical ecosystems will allow us to continue our efforts to grow our external collaborations.”
Brett Wells
Related Content
Addenbrooke’s hospital offers first self-service digital eye test
Addenbrooke’s Hospital, Cambridge, has become the first in the UK to deploy a digital self-testing …
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
CARBOGEN AMCIS manufacturing license advances services in China
Swiss pharma manufacturing company, CARBOGEN AMCIS, has announced that its facility in Shanghai, China, has …
